Park Avenue Securities’s Neurogene NGNE Stock Holding History

Park Avenue Securities’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-814	Closed	-$195K	–	865
2020 Q3	$195K	Buy	+814	New	+$197K	0.01%	709

Other funds holding NGNE

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Park Avenue Securities's NGNE Position: Q4 2020 in Review

Park Avenue Securities sold out of Neurogene (NGNE) in Q4 2020, closing a stake of 814 shares — an estimated $195K sold.

Park Avenue Securities first reported a position in NGNE in Q3 2020 and held it in 1 quarter. The position peaked at $195K in Q3 2020. 84 funds tracked by Wall St. Rank hold NGNE as of Q4 2020.

Park Avenue Securities reported no remaining Neurogene position as of Q4 2020 after selling out during the quarter.
Park Avenue Securities sold 814 Neurogene shares in Q4 2020, an estimated $195K.
Park Avenue Securities first reported a position in Neurogene in Q3 2020 and held it in 1 quarter.
Park Avenue Securities's Neurogene position peaked at $195K in Q3 2020.
84 funds tracked by Wall St. Rank held Neurogene as of Q4 2020.

Based on Park Avenue Securities's 13F filing for Q4 2020, filed 20 Jan 2021.